Increased osteoclastic activity of the acute Charcot foot
Research type
Research Study
Full title
Is cathepsin K inhibition a novel therapeutic target to reduce the increased osteoclastic activity of the acute Charcot foot?
IRAS ID
201145
Contact name
Nina Petrova
Contact email
Sponsor organisation
King's College Hospital NHS Foundation Trust
Duration of Study in the UK
1 years, 0 months, 31 days
Research summary
Some people with diabetes and nerve damage can develop a devastating form of bone and joint disease known as the “Charcot foot” in which there is considerable bone destruction, caused by cells called osteoclasts.
The aim of this study is to measure a specific protein called cathepsin K, which the osteoclasts produce and release during the process of bone breaking. We want to measure the activity of this protein in the laboratory in people with Charcot foot and also in people without diabetes.
If we show that in people with Charcot foot there is increased activity of Cathepsin K, this will help us understand the process of bone destruction. This may also lead to a new treatment for this devastating condition by using special treatment to block the activity of cathepsin K.REC name
East of England - Cambridge South Research Ethics Committee
REC reference
16/EE/0264
Date of REC Opinion
14 Jul 2016
REC opinion
Further Information Favourable Opinion